Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge

Kidney International

Volumn 76, Issue 3, 2009, Pages 331-341

  Chan, Kevin E ^a   Lazarus, J Michael ^a   Wingard, Rebecca L ^a   Hakim, Raymond M ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Anemia management; Dialysis; Hospitalization; Vitamin D

Indexed keywords

ALBUMIN; CALCIUM; ERYTHROPOIETIN; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ANEMIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HAZARD RATIO; HEMODIALYSIS PATIENT; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; OUTPATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANEMIA; BODY WEIGHT; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT READMISSION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 67651095781     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.199     Document Type: Article

References (41)

1. Atlas of chronic kidney disease and end-stage renal disease in the United States. Renal Data Systems. USRDS 2007 Annual Data Report: National Institutes of Diabetes and Digestive and Kidney Disease. Bethesda, MD, 2007.
2. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
4. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
5. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
6. Jack BW, Chetty VK, Anthony D et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med2009; 150: 178-187.
7. Kripalani S, Jackson AT, Schnipper JL et al. Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. J Hosp Med 2007; 2: 314-323.
8. Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 1997; 12: 657-659.
9. Port FK. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46: 1728-1737.
10. Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451.
11. Moore C, Wisnivesky J, Williams S et al. Medical errors related to discontinuity of care from an inpatient to an outpatient setting. J Gen Intern Med 2003; 18: 646-651.
12. Forster AJ, Murff HJ, Peterson JF et al. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005; 20: 317-323.
13. Forster AJ, Clark HD, Menard A et al. Adverse events among medical patients after discharge from hospital. CMAJ 2004; 170: 345-349.
14. Forster AJ, Murff HJ, Peterson JF et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003; 138: 161-167.
15. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure. Med Care 2005; 43: 246-255.
16. Mentari EK, DeOreo PB, O'Connor AS et al. Changes in Medicare reimbursement and patient-nephrologist visits, quality of care, and health-related quality of life. Am J Kidney Dis 2005; 46: 621-627.
17. Plantinga LC, Fink NE, Sadler JH et al. Frequency of patient-physician contact and patient outcomes in hemodialysis care. J Am Soc Nephrol2004; 15: 210-218.
18. Plantinga LC, Fink NE, Jaar BG et al. Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients. J Am Soc Nephrol 2004; 15: 3144-3153.
19. Lazarus JM. Recommended criteria for initiating and discontinuing intradialytic parenteral nutrition therapy. Am J Kidney Dis 1999; 33: 211-216.
20. Nissenson AR, Dylan ML, Griffiths RI et al. Septicemia in patients with ESRD is associated with decreased hematocrit and increased use of erythropoietin. Clin J Am Soc Nephrol 2006; 1: 505-510.
21. Muhammad YS, Leiser J, Moliteris BA. Erythopoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001; 21: 390-396.
22. U.S.Food and Drug Administration. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http:// www.fda.gov/Cder/Drug/InfoSheets/HCP/RHE200711HCP.htm. 11-8-2007. Ref Type: Electronic Citation.
23. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932.
24. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM et al. Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int2005; 68: 2794-2800.
25. Plantinga LC, Fink NE, Jaar BG et al. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Serv Res 2007; 7: 5.
26. Lacson Jr E, Ikizler TA, Lazarus JM et al. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 2007; 17: 363-371.
27. Owen Jr WF, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006.
28. Eknoyan G, Levin NW, Steinberg E: The National Kidney Foundation Dialysis Outcomes Quality Initiative. Curr Opin Nephrol Hypertens 1997; 6: 520-523.
29. Ofsthun NJ, Lazarus JM. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif2007; 25: 31-35.
30. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
31. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
32. Miskulin DC, Martin AA, Brown R et al. Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19: 413-420.
33. van Manen JG, Korevaar JC, Dekker FW et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; 40: 82-89.
34. Liang KY ZS. Longitudinal data analysis using generalized linear models. Biometrika 2008; 73: 13-22.
35. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effect. Biometrika 1983; 70: 41-55.
36. Imbens G. The role of propensity score in estimating dose-response in observational studies for causal effect. Biometrika 2000; 3: 706-710.
37. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987; 82: 387-394.
38. Hirano K IG. Estimation of causal effects using propensity score weighting: an application to data on right heart catherization. Health Serv Outcomes Res Methodol 2001; 2: 259-278.
39. Kosanke JBE. Gmatch: SAS macro. http://mayoresearch.mayo.edu/mayo/ research/biostat/upload, 2004.
40. Rubin D. Matching to remove bias in observational studies. Biometrics1973; 29: 159-183.
41. Lau AH, How PP. The role of pharmacist in the identification and management of secondary hyperparathyroidism. http://www.uspharmacist. com/index.asp?page=ce/105514/default.htm, 2007. Ref Type: Journal (Full).